Key result
Rapamycin prevents and suppresses aortic dissection in mice by modulating the mTOR pathway.
Why the study?
Although rapamycin has been reported to prevent aortopathies in mouse models, its mode of action in aortic dissection has yet to be clarified.
Does rapamycin prevent the development and suppress the progression of aortic dissection in a mouse model?
Does rapamycin prevent the development and suppress the progression of aortic dissection in a mouse model?
Rapamycin effectively prevents the development and suppresses the progression of aortic dissection in a mouse model by modulating the mTOR pathway and maintaining the contractile phenotype of smooth muscle cells.
Answers are grounded in this paper and cite their sources.
Should not change clinical practice; leaves open mTOR inhibition as a hypothesis for human aortic dissection trials.
Aortic dissection (AD) is a serious clinical condition that is unpredictable and frequently results in fatal outcome. Although rapamycin, an inhibitor of mechanistic target of rapamycin (mTOR), has been reported to be effective in preventing aortopathies in mouse models, its mode of action has yet to be clarified. A mouse AD model that was created by the simultaneous administration of β-aminopropionitrile (BAPN) and angiotensin II (AngII) for 14 days. Rapamycin treatment was started either at day 1 or at day 7 of BAPN+AngII challenge, and continued throughout the observational period. Rapamycin was effective both in preventing AD development and in suppressing AD progression. On the other hand, gefitinib, an inhibitor of growth factor signaling, did not show such a beneficial effect, even though both rapamycin and gefitinib suppressed cell cycle activation in AD. Rapamycin suppressed cell cycle-related genes and induced muscle development-related genes in an AD-related gene expression network without a major impact on inflammation-related genes. Rapamycin augmented the activation of Akt1, Akt2, and Stat3, and maintained the contractile phenotype of aortic smooth muscle cells. These findings indicate that rapamycin was effective both in preventing the development and in suppressing the progression of AD, indicating the importance of the mTOR pathway in AD pathogenesis.
No takes yet. Share an insight, caveat, or question.
Hayashi-Hori et al. (2020) studied Aortic dissection. Rapamycin vs. Gefitinib / Untreated was evaluated on AD development and progression. Rapamycin was effective in preventing the development and suppressing the progression of aortic dissection in a mouse model by modulating the mTOR pathway.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: